Corporate VC Backing Influences Private M&A Step-Ups

New data show that including one or more corporate venture investors in a syndicate actually translates into a higher median step-up valuation.

In the wake of the 2008–2009 financial crisis, there has been a decided uptick in corporate venture activity; as traditional venture investors aim to convince LPs to recommit to their funds, they've shifted to later-stage investing, in the hopes of shortening the time to exit. That's created a window of opportunity for strategic investors, who can tap into more innovative projects now at earlier stages. ( See "Corporate Venture Takes Center Stage," START-UP , May 2009 Also see "Corporate Venture Takes Center Stage " - Scrip, 1 May, 2009. and "In the Midst Of A Shakeout, Biotech VCs Must Embrace New Partners, New Math," START-UP , September 2010 Also see "In the Midst Of A Shakeout, Biotech VCs Must Embrace New Partners, New Math" - Scrip, 1 September, 2010..) Bringing in new corporate venture investors at the B or even C round has likely allowed for more up rounds than would have been possible with traditional venture's retrenchment. But there are other advantages as well. In the past, some traditional venture capital firms may have shied away from co-investing with corporate entities. Conventional wisdom suggested that the involvement of such groups might preclude a syndicate's ability to structure an aggressive bidding war for a portfolio company, resulting in a lower overall return. But an analysis by START-UP shows such logic to be outdated. Far from capping an exit, new data show that including one or more corporate venture investors in a syndicate actually translates into a higher median step-up valuation.

Using Elsevier's Strategic Transactions, START-UP identified 92 private biopharma acquisitions completed since 2006. Device, diagnostics, and services companies were excluded....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.